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LOW HEMOGLOBIN LEVEL PRE-BMT IS ASSOCIATED WITH HIGHER
RBC TRANSFUSION RATES AND POORER SURVIVAL IN ALLOGENEIC
BMT RECIPIENTS
Huebsch, L.1; Toze, C.2; Roy, J.3; McDiarmid, S.4; Fergusson, D.1;
Hutton, B.1; Messner, H.5 1. University of Ottawa, Ottawa Hospital,
Ottawa, ON, Canada; 2. University of British Columbia, Vancouver
General Hospital, Vancouver, BC, Canada; 3. Universite´ de Montre´al,
Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; 4. Ottawa
Hospital, Ottawa, ON, Canada; 5. Univerity of Toronto, Princess Mar-
garet Hospital, Toronto, ON, Canada.
Purpose: Data collected from a single Canadian center have
shown an association between pre-transplant hemoglobin (Hgb)
levels and survival (Xenocostas, Transfusion 2002). To conﬁrm
this hypothesis, we undertook an observational cohort study from
3 additional Canadian BMT Programs analyzing the impact of red
blood cell (RBC) transfusions following allogeneic bone marrow
transplant (BMT) and their association with important risk factors.
Methods: Data from 728 allo BMT recipients transplanted be-
tween 01/1995 and 03/2000 were analyzed. We calculated the
mean number of RBC transfusions provided to patients in three
time periods following BMT (0–60 days, 61–120 days, 121–180
days). Variables studied included pre-BMT Hgb level (
100 g/L,
101–110 g/L, 111–120 g/L, 121–130 g/L, 130 g/L), age (
40 vs
40), gender, disease status (early vs advanced), major ABO mis-
match, donor type (related vs unrelated), acute GVHD grade (0-I
vs II-IV), HLA match (6/6 vs 5/6) and source of progenitor cells.
Failure-time analysis was also performed using Cox Proportional
Hazards modeling to examine the impact of low vs high pre-BMT
Hgb level (
110 g/L vs 110 g/L) as well as other risk factors on
day 180 mortality. Results: A total of 11 271 units of RBCs were
transfused during the study period. Demands within the ﬁrst 60
days following BMT totaled 10.6	 9.96 units/patient, declining to
4.02 	 8.41 between 61–120 days and 1.75 	 5.11 units between
121–180 days. RBC transfusion needs increased in the ﬁrst 60 days
in patients with lower pre-BMT Hgb levels, graft from an unre-
lated donor, acute GVHD grades of II-IV, blood as stem cell
source, advanced disease status or a major ABO mismatch (all
p
0.05). Beyond 60 days, only the latter 4 risk factors displayed a
signiﬁcant association with RBC use. Following adjustment, higher
mortality was found to be signiﬁcantly associated with low pre-
BMT Hgb (hazard ratio (HR) 1.61; 95% CI 1.19–2.17), older age
(HR 1.69; 95% CI 0.45–0.79), advanced disease status (HR 1.64;
95% CI 1.14–2.36), use of an unrelated donor (HR 1.56; 95% CI
1.14–2.13), and non-identical HLA match (HR 2.04; 95% CI
0.33–0.73). Conclusions: Pre-BMT Hgb level is an independent
risk factor for increased RBC transfusion requirements between
0–60 days following allo BMT, but has little impact afterwards. In
addition, a lower pre-BMT Hgb level is an independent risk factor
for day 180 mortality. Prospective studies focusing on pre-BMT
Hgb correction are now required.
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SIGNIFICANT DECLINE IN PULMONARY ENGRAFTMENT SYNDROME
AFTER NONMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION ASSOCIATED WITH LESS AMPHOTERICIN USE FOR
FEBRILE NEUTROPENIA
Donohue, T.1; Gorak, E.2; McGettigan, C.2; Morgan, T.2; Fadell, A.2;
Srinivasan, R.1; Childs, R.1 1. Hematology Branch, NHLBI, National
Institutes of Health, Bethesda, MD; 2. Walter Reed Army Medical
Center, Washington, DC.
Pulmonary engraftment syndrome (PES) involves a constellation
of symptoms associated with noninfectious pulmonary injury that
occur during neutrophil recovery after hematopoietic stem-cell
transplantation (HCT). We analyzed the incidence, severity
and risk factors associated with PES in a cohort of 149 consecu-
tive patients (pts) undergoing a cyclophosphamide/ﬂudarabine
based nonmyeloablative allogeneic HCT from November 1997
through April 2002 (cohort-1). Fifteen pts (10%) developed
PES. The incidence of PES was signiﬁcantly higher in pts who
received amphotericin formulations after transplant conditioning
(p0.0026). In a multivariate analysis, older pt age, female gender
and treatment with amphotericin were predictors for the develop-
ment of PES. Although intravenous methylprednisolone resulted
in rapid resolution of PES, median survival was shorter in PES pts
(168 days) compared to those who did not develop this complica-
tion (418 days; p0.0096). This reduction in survival was largely
due to an increased incidence of transplant related mortality in
PES pts compared to non PES pts (KM probability 57% vs. 24%;
p0.0004). Recently, several new broad spectrum anti-fungal
agents have become available for the empiric treatment of febrile
neutropenia unresponsive to antibacterial therapy. Following FDA
approval of voriconazole in May 2002, we performed 41 consecu-
tive transplants through September 2004 in pts with non-malig-
nant hematological disorders and malignant diseases using the
same nonmyeloablative transplant strategy (cohort-2). Median pt
age was similar in cohort-1 and cohort-2 (48 vs 46 years; pn.s.).
Although cohort-2 had a higher percentage of females (previously
deﬁned as a risk factor for PES) compared to cohort-1 (44% vs
27% respectively; p 0.225), the incidence of PES was signiﬁ-
cantly lower in cohort-2 (0%) compared to cohort-1 (10%;
p0.045). In cohort-1, 30/149 pts (20%) received an empiric
amphotericin formulation for febrile neutropenia including 8
(27%) who developed PES. In cohort-2, a similar number of pts
(12/41; 29%) received empiric broad spectrum anti-fungal therapy
for persistent febrile neutropenia (6 voriconazole, 2 caspofungin, 3
amphotericin, and 1 voriconazole followed by caspofungin), none
of whom developed PES (p0.172). These data suggest the use of
newer, non-amphotericin-based antifungal agents as empiric ther-
apy for febrile neutropenia, might reduce the incidence of PES
following allogeneic HCT.
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GENERATION OF CMV SPECIFIC CYTOLYTIC CD4 AND CD8 T-CELLS
BY SENSITIZATION WITH A SINGLE PENTADECAPEPTIDE OF CMV PP65
CONTAINING BOTH MHC CLASS I AND CLASS II EPITOPES
Trivedi, D.; Koehne, G.; Barnett, L.; Doubrovina, E.; O’Reilly, R.
Memorial Sloan Kettering Cancer Center, New York, NY.
CMV infection is a major cause of infectious mortality and
morbidity after hematopoietic cell transplantation (HCT). Studies
suggest that transfer of CMV speciﬁc CD8 T-cells, generated
in-vitro, can provide short-term protection against CMV infection.
However, these cells fail to persist in the absence of CD4 T-cell
help. Recently, we have explored the use of a pool of 138 synthetic
overlapping pentadecapeptides over-spanning the entire sequence
of CMV pp65 to generate CMV speciﬁc T-cells from individuals
of different HLA genotypes. Pentadecapeptides within the pool
eliciting CD4 or CD8 T-cells have then been identiﬁed by
analysis of secondary responses to a mapping grid of pentadecapep-
tide sub-pools with single overlaps. Restricting HLA alleles have
been identiﬁed by examining T-cell responses by intracellular
interferon-gamma (IFN-) production and cell-mediated cytotox-
icity against targets loaded with the identiﬁed pentadecapeptide
and sharing with the T-cell effectors single HLA class I or II
alleles. In a series of CMV seropositive donors, we identiﬁed 5
donors who inherited HLA-A*0201, 4 of whom co-inherited
HLA-DQB1*03. T-cells from each donor, bearing HLA-A*0201
generated A*0201 restricted CD8 T-cells reactive against penta-
decapeptide no. 123 (AGILA RNLVP MVATV) which were found
to be speciﬁc for the known immunogenic nonamer NLVPM-
VATV. In addition, the donors co-inheriting DQB1*03 generated
CD4 T-cells restricted by HLA class II alleles and speciﬁc for the
11-mer (ARNLV PMVATV). Sensitization of the T-cells initially
with this pentadecapeptide consistently elicited both CD4 and
CD8 peptide speciﬁc T-cells. In contrast, stimulation with the
NLVPMVATV nonamer selectively induced CD8 HLA-A*0201
restricted T-cells. Exploration of 15-mers or larger sequences that
can be edited by exopeptidases and presented by other commonly
co-inherited HLA class I and II alleles may identify similar peptide
sequences that can effectively elicit both CD4 and CD8 virus-
speciﬁc T-cell responses for use in adoptive immunotherapy and in
the design of peptide-based vaccines.
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